← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,848	+98	+6%	$156B
2	2 Danaher DHR $158B	1,633	+49	+3%	$121B
3	3 Novartis NVS $279B	1,118	-11	-1%	$19.7B
4	4 Regeneron Pharmaceuticals REGN $80.1B	907	-26	-3%	$51.6B
5	5 Illumina ILMN $41B	899	+7	+0.8%	$41.4B
6	6 Agilent Technologies A $49.1B	767	+20	+3%	$27.1B
7	7 Revvity RVTY $17B	531	+67	+14%	$12.8B
8	8 Charles River Laboratories CRL $14.4B	491	+25	+5%	$10.6B
9	9 DELISTED CATALENT, INC. CTLT	452	+71	+19%	$13.9B
10	10 Sarepta Therapeutics SRPT $1.78B	404	-5	-1%	$10.1B
11	11 Ionis Pharmaceuticals IONS $7.1B	368	-8	-2%	$5.63B
12	12 Alnylam Pharmaceuticals ALNY $30B	357	-18	-5%	$15.8B
13	13 Guardant Health GH $21.9B	346	+21	+6%	$9.55B
14	14 CRISPR Therapeutics CRSP $4.86B	309	+33	+12%	$4.01B
15	NVTA 15 DELISTED Invitae Corporation NVTA	285	+61	+27%	$6.11B
16	16 DELISTED bluebird bio BLUE	275	-3	-1%	$3.41B
17	17 Azenta AZTA $1.63B	269	0	0%	$3.35B
18	18 Arrowhead Research ARWR $8.25B	262	+12	+5%	$2.94B
19	19 Qiagen QGEN $9.41B	253	-23	-8%	$5.34B
20	20 ARK Genomic Revolution ETF ARKG $2.05B	242	+74	+44%	$761M
21	21 Bruker BRKR $8.47B	241	+14	+6%	$4.12B
22	22 Editas Medicine EDIT $349M	239	+1	+0.4%	$1.55B
23	23 10x Genomics TXG $9.52B	219	+73	+50%	$8.55B
24	24 Fate Therapeutics FATE $232M	211	+9	+4%	$3.51B
25	25 DELISTED SANGAMO THERAPEUTICS INC SGMO	210	+5	+2%	$772M